Enzyme That Sensitizes Cells To Chemotherapeutics Could Also Be New Anti-cancer Target

Main Category: Cancer / Oncology
Also Included In: Lung Cancer
Article Date: 20 Aug 2008 - 3:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:5 stars

5 (2 votes)

Healthcare Prof:not yet rated


Researchers at Van Andel Institute (VAI) and Novartis Institutes for Biomedical Research have identified an important enzyme required for cancer cell survival. Lowering levels of the enzyme caused a wide variety of cancer cells to die, reduced proliferation of cancer cells, and sensitized cancer cells to commonly used chemotherapeutic agents, such as the drug Taxol. The cells in the study included pancreatic, prostate, and lung cancer cells.

"We have identified a previously unrecognized anti-cancer target," said VAI Scientific Investigator Jeff MacKeigan, Ph.D. "For some reason, cancer cells become 'addicted' to certain genes. When we blocked the gene that results in the enzyme PI3K-C2alpha using a fairly new tool used extensively by our lab called RNA interference, we found this had an abrupt adverse effect on a variety of cancer cells."

The findings, published in Molecular Cancer Research, examined the role of an often overlooked class of phosphoinositide 3-kinase enzymes and found that one of the enzymes, called PI3K-C2alpha, was required for several types of cancer cells to survive. Researchers found that lowering levels of this enzyme reduced proliferation in a number of cancer cell lines, and they were able to determine a critical threshold level of PI3K-C2alpha below which cell death was "switched on."

"Although we must further determine what happens in normal cells to confirm the therapeutic value, we also found that decreasing levels of PI3K-Class 2 alpha to a certain point didn't kill the cancer cells, but did sensitize them to chemotherapeutic agents such as Taxol," said MacKeigan. "This alone could contribute to a more effective anti-cancer strategy in a subset of cancers."

Established by Jay and Betty Van Andel in 1996, Van Andel Institute is an independent research organization dedicated to preserving, enhancing and expanding the frontiers of medical science, and to achieving excellence in education by probing fundamental issues of education and the learning process.

Van Andel Institute

View drug information on Taxol.


Article adapted by Medical News Today from original press release.
Visit our cancer / oncology section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Van Andel Institute. "Enzyme That Sensitizes Cells To Chemotherapeutics Could Also Be New Anti-cancer Target." Medical News Today. MediLexicon, Intl., 20 Aug. 2008. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/118760.php>

APA
Van Andel Institute. (2008, August 20). "Enzyme That Sensitizes Cells To Chemotherapeutics Could Also Be New Anti-cancer Target." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/118760.php.

Please note: If no author information is provided, the source is cited instead.


Cancer / Oncology

What is Cancer?

Cancer is a class of diseases characterized by out-of-control cell growth. There are over 100 different types of cancer, and each is classified by the type of cell that is initially affected. Read more...

Most Popular Articles



Follow Our Cancer News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Cancer / Oncology Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »